Breaking News
January 23, 2019 - New certified reference material for testing residual solvents in cannabis
January 23, 2019 - Gene-edited chickens could prevent future flu pandemic
January 23, 2019 - Cardiovascular disease risk begins even before birth
January 23, 2019 - Younger patients receiving kidney transplant more likely to live longer, shows data
January 23, 2019 - Skin samples hold early signs of prion disease, research suggests
January 23, 2019 - Researchers discover how body initiates repair mechanisms that limits damage to myelin sheath
January 23, 2019 - Fecal transplant from certain donors better than others
January 23, 2019 - Risk for Uninsurance in AMI Patients Reduced With Medicaid Expansion
January 23, 2019 - Readmissions reduction program may be associated with increase in patient-level mortality
January 23, 2019 - Fostering translation and communication in medicine and beyond
January 23, 2019 - To Fight Fatty Liver, Avoid Sugary Foods and Drinks
January 23, 2019 - TPU scientists develop new implants that double the rate of bone lengthening in kids
January 23, 2019 - New sessions at Pittcon 2019
January 23, 2019 - Insilico to present latest findings in AI for Drug Discovery at 3rd Annual SABPA FTD Forum
January 23, 2019 - Opioid overdose patients can be safely discharged an hour after administration of naloxone
January 23, 2019 - Scientists find bacterial extracellular vesicles in human blood
January 23, 2019 - Researchers gain new insights into development of necrotizing enterocolitis in preemies
January 23, 2019 - Medical expert advises people with epilepsy not to stockpile medicines
January 23, 2019 - Study outlines research priorities for improving pediatric patient care and safety
January 23, 2019 - Bedfont to exhibit NObreath FeNO monitor at Arab Health 2019
January 23, 2019 - Nicotinamide riboside supplementation confers significant physiological benefits to mothers and offspring
January 23, 2019 - Increasing temperatures may help preserve crop nutrition
January 23, 2019 - Many Oncologists in the Dark About LGBTQ Health Needs
January 23, 2019 - Epigenetic change causes fruit fly babies to inherit diet-induced heart disease
January 23, 2019 - Erasing memories could reduce relapse rates among drug addicts
January 23, 2019 - African Americans who smoke cigarettes are more likely to develop peripheral artery disease
January 23, 2019 - Unique data combination helps FinnGen researchers to fund links between genetic factors and health
January 23, 2019 - Parents’ mental health problems associated with reactive attachment disorder in children
January 23, 2019 - Graphene Flagship project studies impact of graphene and related materials on our health
January 23, 2019 - The connection between the Pope and contraceptive pills
January 23, 2019 - Prior dengue infection could protect children from symptomatic Zika
January 23, 2019 - Previous dengue virus infection associated with protection from symptomatic Zika
January 23, 2019 - VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance
January 23, 2019 - The Tiny Camera That Could Revolutionize Cardiovascular Surgery
January 23, 2019 - Peptide isolated from soil fungi has antitumor and antibacterial properties
January 23, 2019 - TGen identifies polio-like virus as potential cause of Acute Flaccid Myelitis outbreak
January 23, 2019 - Migrants and refugees do not bring disease and are at greater health risk themselves says WHO
January 23, 2019 - Examing the effects of menopause in workplace
January 23, 2019 - Enemy number 1 – Air pollution and climate change top of WHO agenda
January 23, 2019 - Two Positive Phase III studies of Tafenoquine for the Radical Cure of Plasmodium vivax Malaria Published in The New England Journal of Medicine
January 23, 2019 - World Trade Center responders at increased risk for head and neck cancers
January 23, 2019 - Low-sugar diet leads to significant improvement in nonalcoholic fatty liver disease in boys
January 23, 2019 - Chaos in bodily regulation can optimize our immune system, finds study
January 23, 2019 - Short, text-based exercises can increase happiness for adults recovering from substance use disorders
January 23, 2019 - Body size may have greater influence on women’s lifespan than men
January 23, 2019 - Groundbreaking tool helps visualize neuronal activity with near-infrared light
January 23, 2019 - Prior dengue immunity in children may be protective against symptomatic Zika
January 23, 2019 - Holocaust survivors with PTSD and their offspring exhibit more unhealthy behavior patterns
January 23, 2019 - Scientists discover new genetic mutations causing inherited deaf-blindness
January 23, 2019 - UC team designs new naloxone-dispensing smart device
January 23, 2019 - Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
January 23, 2019 - Brain activity shows development of visual sensitivity in autism
January 23, 2019 - Two hour gap between dinner and sleep is overrated says Japanese research
January 23, 2019 - Fear and embarrassment are causing smear test numbers to plummet
January 23, 2019 - Protein-secreting device implanted in epileptic rats reduces seizures, improves cognition
January 23, 2019 - Reintroduction project recovers current wild population of green turtle in Cayman Islands
January 23, 2019 - Cancer survivors face greater financial burden related to medical bills
January 23, 2019 - PSA screening reduces prostate cancer deaths by 30%
January 23, 2019 - LSTM receives grant to help improve health of people living in informal settlements
January 23, 2019 - Hemochromatosis Mutation Linked to Other Morbidity
January 23, 2019 - Why early diagnosis of autism should lead to early intervention
January 23, 2019 - Aspirin May Lower Stroke Risk in Women with History of Preeclampsia
January 23, 2019 - Exposure to certain chemicals may be linked to decrease in blood pressure during pregnancy
January 23, 2019 - Bowel cancer on the rise among younger Australians
January 23, 2019 - Scientists have reversed memory loss in a mouse model of Alzheimer’s
January 23, 2019 - Defective molecular master switch could lead to age-related macular degeneration
January 23, 2019 - Researchers identify how concussions may contribute to seizures
January 23, 2019 - Short interval between last meal of the day and bedtime may not affect blood glucose levels
January 23, 2019 - Still Too Many Highway Deaths Tied to Speeding
January 23, 2019 - Prenatal valproate exposure linked to increased ADHD risk
January 23, 2019 - Compound identified that may help treat heart failure
January 23, 2019 - Undiagnosed Asthma in Urban Adolescents May Be Common
January 23, 2019 - Study describes metabolism of intestinal microbiota in babies for the first time
January 22, 2019 - Study links concussions to development of epilepsy
January 22, 2019 - Specialist-led hospital bereavement service may help restrain legal action after difficult deaths
January 22, 2019 - Genetic study reveals possible new routes to treating osteoarthritis
January 22, 2019 - Blood test may detect early signs of lung-transplant rejection
January 22, 2019 - Blood marker could aid in early prediction of Alzheimer’s progression
January 22, 2019 - Orthodontic treatment does not guarantee future dental health
January 22, 2019 - Rutgers researchers discover cause of bone loss in people with joint replacements
Problems Continue To Plague Tumor Biomarker Tests

Problems Continue To Plague Tumor Biomarker Tests

image_pdfDownload PDFimage_print

Action Points

  • Not all tumor biomarker assays regarded as high-quality are highly congruent or have clinical relevance, according to results from two separate comparison studies.
  • Note that while laboratory-developed tests (LDTs) and FDA-approved companion diagnostics (FDA-CDs) both demonstrated a high degree of accuracy and excellent performance using uniform reference materials, results of analyses on non-standard materials show significant variability.

Not all high-quality tumor biomarker assays are highly congruent or have clinical relevance, results from two separate comparison studies showed.

In the first, laboratory-developed tests (LDTs) and FDA-approved companion diagnostics (FDA-CDs) both demonstrated a high degree of accuracy and excellent performance overall for three oncology analytes in College of American Pathologists (CAP) proficiency testing (PT), researchers said.

Pathological evaluation of tumors comparing LDTs and FDA-CDs in 6,897 proficiency responses showed that both test types exceeded 97% accuracy across all comparable molecular oncology proficiency testing samples for BRAF, EGFR, and KRAS genes, according to Annette S. Kim, MD, PhD, of Brigham and Women’s Hospital in Boston, and colleagues.

“These findings support both the excellent and equivalent performance of both LDTs and FDA-CDs in clinical diagnostic testing,” the study authors wrote in JAMA Oncology.

However, a comparison of laboratories’ pre-analytic practices showed more than 60% were using FDA-CDs outside the bounds of FDA-approved methods. Although participants said they made modifications to the FDA-CDs to increase the flexibility of clinical practice, this effectively rendered the assays LDTs, the study authors noted.

“Both FDA-CD and LDT laboratories accept a wide range of specimen preparations, as well as tumor types,” Kim and colleagues said. “Although this flexibility is advantageous for patient care, it is important to recognize that the use of specimens other than formalin-fixed paraffin-embedded samples of the specified tumor type for the FDA-CDs is off-label, resulting in reclassification of the assay as an LDT.”

Laboratories used the assay off-label by accepting specimens with lower tumor content than required for the approved FDA-CD assay, the study revealed. Other practice modifications included accepting unapproved specimen and tumor types, and not quantifying DNA before performing the FDA-CD assay.

In the study, PT responses were included for 2,524 BRAF (14 PT samples), 2,216 EGFR (11 PT samples), and 2,157 KRAS (10 PT samples). Approximately 15% of these assays were performed using commercially available FDA-CD kits and 85% were analyzed as LDTs.

There were no significant differences between LDTs and the FDA-CD acceptability rates for KRAS. The FDA-CDs performed less well than the LDTs for BRAF p.V600K analysis (CD 66.1% versus LDT 88.0%), and the LDT assay was inferior for EGFR p.L861Q mutation (CD 100% versus LDT 91%).

Noting the comparable performance of the two assays, the greater clinical relevance of LDTs and the “significant off-label use of FDA-CDs,” it might make more sense to reclassify FDA-CDs as LTDs, the researchers suggested.

In an accompanying editorial, Daniel F. Hayes, MD, of the University of Michigan Comprehensive Cancer Center, Ann Arbor, noted that a tumor biomarker test that has analytical validity but lacks clinical utility can’t be introduced into routine practice. “Therefore, approval of a tumor biomarker test by the FDA does not necessarily imply that it should be ordered or used to direct patient care,” he said.

In the era of precision oncology medicine, clinicians need to be knowledgeable about tumor biomarkers as well as the tests used to measure them, he added.

Although Hayes called the CAP proficiency testing “terrific” and said it “should make all of us who are clinicians sleep better at night,” he also pointed out that the study included only pathologists participating in the CAP proficiency testing.

“You should hope that your patient’s sample was tested in one of these laboratories and not in one that did not include these proficient pathologists,” he commented.

The number of tested specimens was low, Hayes said, who also zeroed in on the fact that more than half of the laboratories using FDA-CDs didn’t follow manufacturer’s instructions.

“Although it is reassuring that different laboratories using different techniques and assays usually came up with the same results for BRAF, EGFR, and KRAS, these results cannot be extrapolated to other, more complex tumor tests,” he concluded.

Wide Inter-Test Variability

In a related research letter in the same issue, Gonzalo Torga, MD, and Kenneth J. Pienta, MD, of Johns Hopkins University School of Medicine in Baltimore, reported findings from a small study showing very low patient-paired sample congruence between two liquid commercial biopsy tests. Both genetic tests had self-reported high accuracy, specificity, and sensitivity to detect and quantify tumor-specific alteration, and both laboratories were CAP-accredited for cfDNA next-generation sequencing.

However, in 40 patients with metastatic prostate cancer, 6 blood samples were unevaluable. In the remaining 34 samples, complete concordance between the two assays was observed in 9 (35%). The assays were partially concordant in six samples of the remaining 25, but in the last 16 samples, there was no concordance between the assays at all.

“These data cannot determine which test is more accurate but suggest that reported gene alterations will not be the same across different platforms, raising the specter that patients could potentially receive different treatments depending on the cfDNA platform,” the study authors said.

These results are “disturbing,” said Hayes, and have obvious implications for every clinician ordering laboratory-developed tests. Although LTDs have made important contributions to patient care, a lot of uncertainty remains about their accuracy and basis for use, Hayes added.

“I have often said that ‘a bad tumor biomarker test is as bad as a bad drug.’ Caveat emptor is not a good way to practice medicine, and I for one will continue to call for collegial and constructive measures to improve, and in many cases further regulate, tests that are so important for our patients.”

Lead study author Kim reported a relationship with Aushon Biosciences and a number of study co-authors also reported relationships with industry. Second study authors Torga and Pienta disclosed no potential conflicts of interest. Editorialist Hayes reported relationships with OncImmune, Inbiomotion, Merrimack Pharmaceuticals, Eli Lilly Company, Janssen, Menarini/Silicon bioSystems, Puma Biotechnology, Pfizer, AstraZeneca, and Menarini/Silicon bioSystems.

2017-12-19T13:30:00-0500

Tagged with:

About author

Related Articles